Dr. Melotek on Cetuximab Added to Chemotherapy and Chemoradiation in Head and Neck Cancer

James Melotek, MD
Published: Monday, Feb 22, 2016



James Melotek, MD, Radiation and Cellular Oncology, University of Chicago Medicine, discusses an analysis of a phase II study examining the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation therapy for locoregionally advanced head and neck cancer.

The randomized trial’s two primary endpoints were to compare the efficacy of the addition of cetuximab to both therapies with historical control, and to investigate two chemoradiotherapy platforms, Melotek explains. The two platforms consisted of cetuximab 5-FU, and hydroxyurea with concomitant radiotherapy twice daily versus cetuximab, cisplatin and accelerated radiotherapy with delayed concomitant boost.

Results showed that both subgroups performed far superior beyond historical control with the addition of cetuximab, especially in patients who were HPV-negative. No significant survival outcomes were reported between the two chemotherapy platforms, he says.

<<< View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium



James Melotek, MD, Radiation and Cellular Oncology, University of Chicago Medicine, discusses an analysis of a phase II study examining the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation therapy for locoregionally advanced head and neck cancer.

The randomized trial’s two primary endpoints were to compare the efficacy of the addition of cetuximab to both therapies with historical control, and to investigate two chemoradiotherapy platforms, Melotek explains. The two platforms consisted of cetuximab 5-FU, and hydroxyurea with concomitant radiotherapy twice daily versus cetuximab, cisplatin and accelerated radiotherapy with delayed concomitant boost.

Results showed that both subgroups performed far superior beyond historical control with the addition of cetuximab, especially in patients who were HPV-negative. No significant survival outcomes were reported between the two chemotherapy platforms, he says.

<<< View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x